Lee et al. demonstrated that CXCL5 was critical to pancreatic cancer cell resistance to gemcitabine in vivo, where the knockdown of CXCL5 enhanced the inhibitory anti-tumor effects of treatment and promoted apoptosis [70]. This evidence concerns the gene CXCL5 and neoplasm.